Spain’s insulin pumps market is expected to witness steady growth, driven by the increasing prevalence of type 1 diabetes, growing adoption of advanced diabetes management technologies, and rising demand for automated insulin delivery systems. The shift toward personalized, data-driven diabetes care, supported by continuous glucose monitoring (CGM) integration and smart insulin delivery technologies, is accelerating the adoption of next-generation insulin pumps across the country. Amid these trends, Spain’s insulin pumps market is projected to grow at a compound annual growth rate (CAGR) of approximately 8% through 2036, according to GlobalData, a leading intelligence and productivity platform.

Spain’s insulin pumps market is moving into a new growth phase as healthcare systems increasingly prioritize technologies that reduce the day-to-day burden of diabetes management while improving glycemic control.

GlobalData’s report, “Insulin Pumps and Continuous Glucose Monitors Market Size by Segments, Share, Regulatory, Reimbursement and Forecast to 2036,” reveals that Spain accounted for nearly 6% of the Europe insulin pumps market in 2025.

Sarvesh Kumar, Medical Devices Analyst at GlobalData, comments: “As uptake of automated insulin delivery systems rises and connected diabetes care becomes more widely established, demand is expected to increase.”

Within Spain’s evolving diabetes care landscape, the launch of Insulet’s Omnipod 5 marks an important step in expanding access to automated insulin delivery technology. The introduction of a tubeless insulin pump integrated with compatible CGM platforms is expected to support broader adoption of closed-loop diabetes management by offering greater treatment flexibility and simplified insulin delivery.

As reimbursement pathways and regional access continue to expand, the availability of advanced insulin pump technologies is likely to accelerate the transition towards connected, patient-centric diabetes care across Spain.

Kumar concludes: “While the high cost of advanced insulin pump systems and regional reimbursement variations remain key barriers to wider adoption in Spain, continued improvements in automated insulin delivery are expected to drive greater insulin pump adoption and support long-term market growth.”